Cited 0 time in
SELECTING PATIENTS FOR 3RD LINE CHEMOTHERAPY AND BEYOND IN EPITHELIAL OVARIAN CANCER
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Seol, A. | - |
| dc.contributor.author | Lee, M. | - |
| dc.contributor.author | Yim, G. | - |
| dc.date.accessioned | 2024-08-08T03:31:10Z | - |
| dc.date.available | 2024-08-08T03:31:10Z | - |
| dc.date.issued | 2020-11 | - |
| dc.identifier.issn | 1048-891X | - |
| dc.identifier.issn | 1525-1438 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/17129 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | BMJ PUBLISHING GROUP | - |
| dc.title | SELECTING PATIENTS FOR 3RD LINE CHEMOTHERAPY AND BEYOND IN EPITHELIAL OVARIAN CANCER | - |
| dc.type | Article | - |
| dc.publisher.location | 영국 | - |
| dc.identifier.wosid | 000616549600165 | - |
| dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, v.30, pp A82 - A82 | - |
| dc.citation.title | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | - |
| dc.citation.volume | 30 | - |
| dc.citation.startPage | A82 | - |
| dc.citation.endPage | A82 | - |
| dc.type.docType | Meeting Abstract | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Oncology | - |
| dc.relation.journalResearchArea | Obstetrics & Gynecology | - |
| dc.relation.journalWebOfScienceCategory | Oncology | - |
| dc.relation.journalWebOfScienceCategory | Obstetrics & Gynecology | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
